RESULTS	There was no difference among treatment groups at baseline , but at the month 6 primary end point the percentage of patients with CRVO and no RNP was significantly greater in the RBZ groups ( 0.3 mg , 82.0 % , P = 0.0092 ; 0.5 mg , 84.0 % , P = 0.0067 ) versus the sham group ( 67.0 % ) .\